Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2025 07:30 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following...
November 06, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today...
October 29, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 30, 2025 08:45 ET | Source: PolyPid Ltd.

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
September 16, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
September 03, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 02, 2025 08:30 ET | Source: PolyPid Ltd.

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today...
August 13, 2025 07:30 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting...
August 12, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
July 30, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...